The benefits of the AstraZeneca vaccine still outweigh the risks for the vast majority of adults, regulators sayAll under-40s will be offered an alternative to the AstraZeneca vaccine as falling Covid-19 infection rates makes the risk of blood clots loom larger, The Times has learnt. No new safety concerns have emerged over the Oxford vaccine but the Joint Committee on Vaccination and Immunisation (JCVI) will issue “precautionary” advice today that those in their thirties should be offered other jabs as success against the pandemic reduces their risk from Covid-19. SponsoredSupplies of Pfizer-BioNTech and Moderna are sufficient to make up the bulk of remaining first doses, with AstraZeneca largely being used to complete second doses for older people, sources say. More younger people may also be persuaded to get the vaccine if hesitancy caused by side-effect fears is no longer a problem, it

Source: The Times May 06, 2021 21:08 UTC